Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer
Abstract
DOI: 10.26650/experimed.2018.18003
Objectives: Parkinson’s disease (PD) is a
common neurodegenerative disorder that affects >0.2% of the population aged
>40 years. Several studies have reported a low prevalence of cancer in
individuals with PD. Therefore, the PI3K/Akt signaling pathway has received
increasing research attention. Investigating variations in expression levels of
components associated with this pathway might aid in improving novel treatment
methods and biomarkers for PD.
Material and Method: We evaluated expression levels of components of the DJ-1-PI3K/Akt signaling pathway in the peripheral blood mononuclear cells of patients with PD, those with lung cancer (LC), and healthy controls and attempted to identify a possible correlation between expression levels and clinical features of PD.
Results: Levels of phosphatase and tensin homolog (PTEN) and apoptosis-inducing factor-1 significantly decreased, whereas those of insulin-like growth factor 1 (IGF-1) significantly increased in patients with PD than in healthy controls. In patients with LC, levels of PTEN, caspase-3, and α-synuclein significantly increased, whereas those of IGF-1 significantly decreased. Furthermore, a correlation was observed between the clinical subtypes of PD and levels of α-synuclein, IGF-1, caspase-3, DJ-1, mechanistic target of rapamycin, Mdm2, and Akt-1 factors.
Conclusion: Patients with PD showed decreased expression levels of proapoptotic PTEN and increased levels of components of the antiapoptotic PI3K/Akt pathway, which suggests an activation of the antiapoptotic pathway to compensate for the increased neuronal destruction in PD. The correlation between expression levels of components of several PI3K/Akt signaling pathway and clinical parameters suggests that these factors can be used as disability and prognostic markers in patients with PD. Decreased expression levels of antiapoptotic factors in patients with PD having postural instability, in particular, suggests a close relationship between neuronal destruction and this symptom.
Keywords
References
- 1. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 62: 10-5.
- 2. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s Disease: Variation by Age, Gender, and Race/Ethnicity. Am J Epidemiol 2003; 157: 1015-22.
- 3. Hirsch E, Graybiel A, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 1988; 334(6180): 345-8.
- 4. Dias V, Junn E, Mouradian MM. The role of oxidative stress in parkinson’s disease. J Parkinsons Dis 2013; 3: 461-91.
- 5. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson’s disease. Ann Neurol 1985; 17: 505-9.
- 6. Olsen J, Friis S, Frederiksen K. Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease. Epidemiology 2006; 17: 582-7.
- 7. D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G, et al. Tumor diagnosis preceding Parkinson’s disease: A case-control study. Mov Disord 2004; 19: 807-11.
- 8. Elbaz A, Peterson B, Yang P, Van Gerpen J, Bower J, Maraganore D, et al. Nonfatal cancer preceding parkinson’s disease: a case-control study. Epidemiology 2002; 13: 157-64.
Details
Primary Language
English
Subjects
Clinical Sciences
Journal Section
Research Article
Publication Date
November 12, 2018
Submission Date
September 13, 2018
Acceptance Date
September 14, 2018
Published in Issue
Year 2018 Volume: 8 Number: 2